Agilent participates in landmark study
Agilent microarrays have been used in a landmark research study on prenatal samples.
Agilent microarrays have been used in a landmark research study on prenatal samples. The study encompassed three years and 4400 samples and was designed to evaluate the accuracy and potential advantages of using microarray analysis over conventional karyotyping. Researchers from Emory University, Baylor College of Medicine, Columbia University and Signature Genomics all took part in the study.
Most of the samples were uncultured amniotic fluid and chorionic villi and all were sent to a reference lab for chromosome analysis.
The study represents an important milestone in understanding prenatal abnormalities. Dr Laird Jackson, Professor of Genetics, Department of Obstetric and Gynecology, Drexel University College of Medicine, commented, “This landmark research study on prenatal samples will have long-lasting implications to the research community. Microarrays allowed us to detect smaller aberrations compared to traditional karyotyping.”
Seventy one percent of samples were run on Agilent SurePrint CGH microarrays and Agilent software was used for data analysis. Agilent also assisted the research group in developing the arrays used in the study.
For more information please visit ref="http://www.agilent.com">www.agilent.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
